Therapy refractory angioimmunoblastic T‐cell lymphoma in complete remission with lenalidomide | Zendy

Beckers Mariëlle M. | Zendy; Huls Gerwin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Therapy refractory angioimmunoblastic T‐cell lymphoma in complete remission with lenalidomide

Author(s) -

Beckers Mariëlle M.,

Huls Gerwin

Publication year - 2013

Publication title -

european journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.904

H-Index - 84

eISSN - 1600-0609

pISSN - 0902-4441

DOI - 10.1111/ejh.12053

Subject(s) - lenalidomide , angioimmunoblastic t cell lymphoma , refractory (planetary science) , prednisone , medicine , lymphoma , oncology , gastroenterology , dermatology , multiple myeloma , immunology , materials science , t cell , immune system , composite material

The prognosis of therapy refractory angioimmunoblastic lymphoma ( AITL ) is very poor. In this report we describe a patient with AITL refractory to 2 lines of chemotherapy. He was treated with lenalidomide 15 mg continuously and prednisone. After 2 yr follow‐up, the patient has no detectable disease. Lenalidomide was well tolerated without side‐effects. Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research